---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-109802"
form_type: "8-K"
ticker: "QNRX"
cik: "0001671502"
company_name: "Quoin Pharmaceuticals, Ltd."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:16:57.560042+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Quoin achieves 4% and 5% rapamycin loadings in topical and patch; clinical testing planned H1 2026

## Summary
- Rapamycin loading 4% w/w in proprietary topical formulation; 5% w/w in dermal patch system.
- Clinical trial and stability batch manufacture to start Q4 2025; clinical testing in H1 2026.
- Initial targets: Microcystic Lymphatic Malformations and Venous Malformations (no FDA-approved treatments).
- CEO notes capital raise completed to fund Netherton Syndrome pivotal studies and advance rapamycin programs.
- Milestone complements ongoing late-stage Netherton Syndrome and Peeling Skin Syndrome development.

## SEC filing metadata
- accession: 0001104659-25-109802
- form_type: 8-K
- ticker: QNRX
- cik: 0001671502
- company_name: Quoin Pharmaceuticals, Ltd.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671502/000110465925109802/0001104659-25-109802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671502/000110465925109802/tm2530990d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-109802
- JSON: https://secwatch.observer/filing/0001104659-25-109802.json
- Plain text: https://secwatch.observer/filing/0001104659-25-109802.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.